IRLAB Therapeutics AB Class A (DE:6IRA)
FRANKFURT:6IRA
6IRA Stock Chart & Stats
€0.18
-€0.01(-1.25%)
At close: 4:00 PM EST
€0.18
-€0.01(-1.25%)
Day’s Range― - ―
52-Week Range€0.11 - €0.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.35M
Enterprise Value€79.99M
Total Cash (Recent Filing)€50.79M
Total Debt (Recent Filing)€27.08M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding141,430,440
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.24
Revenue Forecast (FY)€8.87M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~60.9% TTM revenue rebound reflects a material recovery in top-line performance versus recent years. Sustained revenue growth over coming quarters reduces reliance on financing, supports continued program funding, and increases the company's ability to attract partners or milestone-driven collaboration revenues.
Manageable LeverageDebt/equity around 0.68 and improvement from 2024 indicate partial balance-sheet repair and moderate leverage. This level preserves near-term financial flexibility, lowers immediate refinancing pressure, and gives management scope to fund R&D or negotiate partnerships without acute solvency risk.
Focused R&D PipelineA concentrated strategy on Parkinson's and CNS disorders creates clear domain expertise and strategic differentiation. Structural unmet needs in neurodegeneration support long-term program optionality, increasing the odds of partnership, licensing, or targeted commercialization outcomes as trials progress.
Bears Say
High Cash BurnOperating and free cash flow near -90M TTM represent substantial ongoing cash burn. This creates near-term dependence on external financing, raises dilution and refinancing risk, and can constrain pacing of clinical programs or commercialization investments if capital markets tighten.
Persistent LossesNegative gross profit and a steep net margin (~-72%) show the business remains unprofitable despite revenue recovery. Persistent losses limit internal funding capacity, extend reliance on capital raises, and increase execution risk as the company advances costly clinical development and seeks commercialization paths.
Eroded Equity BaseSubstantial equity erosion and deeply negative ROE indicate a weakened capital buffer and erosion of shareholder value. A thinner equity base raises vulnerability to adverse shocks, complicates favorable financing terms, and increases the probability of dilutive raises under stress.
IRLAB Therapeutics AB Class A News
6IRA FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.10 and its highest was €0.60 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €16.35M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is Aug 26, 2026 which is in 74 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on May 06, 2026. The company reported €0.01 earnings per share for the quarter, beating the consensus estimate of N/A by €0.01.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 141,430,440 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of €0.01 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -14.634%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
Initiator Pharma A/S
―